

Diabetic kidney disease

Nature Reviews Disease Primers

1, 15018

DOI: [10.1038/nrdp.2015.18](https://doi.org/10.1038/nrdp.2015.18)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment. <i>Diabetes Therapy</i> , 2016, 7, 439-454.	1.2	24
2	Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2016, 12, 73-81.	4.1	441
3	Epigenetic Mechanisms in Diabetic Kidney Disease. <i>Current Diabetes Reports</i> , 2016, 16, 31.	1.7	38
4	Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology. <i>Cell Metabolism</i> , 2017, 26, 27-38.	7.2	233
5	The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. <i>Diabetes and Metabolism</i> , 2017, 43, 2S20-2S27.	1.4	68
6	Genetics of Diabetic Kidney Disease—From the Worst of Nightmares to the Light of Dawn?. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 389-393.	3.0	23
7	Precision Medicine Approaches to Diabetic Kidney Disease: Tissue as an Issue. <i>Current Diabetes Reports</i> , 2017, 17, 30.	1.7	27
8	Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. <i>Kidney International</i> , 2017, 91, 1300-1311.	2.6	159
9	An integrin antagonist (MK-0429) decreases proteinuria and renal fibrosis in the ZSF1 rat diabetic nephropathy model. <i>Pharmacology Research and Perspectives</i> , 2017, 5, e00354.	1.1	41
10	Plasma Leucine-Rich Î±2-Glycoprotein 1 Predicts Rapid eGFR Decline and Albuminuria Progression in Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3683-3691.	1.8	43
11	Epigenetic Regulations in Diabetic Nephropathy. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-6.	1.0	58
12	Diabetic Nephropathy: From Pathophysiology to Treatment. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-2.	1.0	16
13	Lipoxins Regulate the Early Growth Response-1 Network and Reverse Diabetic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1437-1448.	3.0	48
14	Safety and Efficacy of Tenepliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance. <i>Diabetes Therapy</i> , 2018, 9, 1083-1097.	1.2	10
15	Diabetic Kidney Disease: Is There a Role for Glycemic Variability?. <i>Current Diabetes Reports</i> , 2018, 18, 13.	1.7	13
16	The Warburg Effect in Diabetic Kidney Disease. <i>Seminars in Nephrology</i> , 2018, 38, 111-120.	0.6	75
17	Preservation of renal function in chronic diabetes by enhancing glomerular glucose metabolism. <i>Journal of Molecular Medicine</i> , 2018, 96, 373-381.	1.7	21
19	The Global Epidemiology of Diabetes and Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2018, 25, 121-132.	0.6	335

#	ARTICLE	IF	CITATIONS
20	FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 118-137.	3.0	133
21	Renal outcomes with dipeptidyl peptidase-4 inhibitors. <i>Diabetes and Metabolism</i> , 2018, 44, 101-111.	1.4	19
22	Associations between angiotensinogen M235T polymorphisms and the risk of diabetic nephropathy: A meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2018, 142, 26-36.	1.1	5
23	Aberrant DNA methylation of Tgfb1 in diabetic kidney mesangial cells. <i>Scientific Reports</i> , 2018, 8, 16338.	1.6	18
24	Mathematical model of hemodynamic mechanisms and consequences of glomerular hypertension in diabetic mice. <i>Npj Systems Biology and Applications</i> , 2018, 4, 2.	1.4	11
25	Clinical and genetic associations of renal function and diabetic kidney disease in the United Arab Emirates: a cross-sectional study. <i>BMJ Open</i> , 2018, 8, e020759.	0.8	13
26	Prolonged systemic hyperglycemia does not cause pericyte loss and permeability at the mouse blood-brain barrier. <i>Scientific Reports</i> , 2018, 8, 17462.	1.6	19
27	Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with type 2-diabetes and microalbuminuria. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 1133-1140.	1.2	9
28	New clinical trial designs for establishing drug efficacy and safety in a precision medicine era. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 14-18.	2.2	19
29	Histone Deacetylase Inhibitors and Diabetic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2630.	1.8	62
30	Tiaolipiwei Acupuncture Reduces Albuminuria by Alleviating Podocyte Lesions in a Rat Model of Diabetic Nephropathy. <i>Evidence-based Complementary and Alternative Medicine</i> , 2018, 2018, 1-10.	0.5	5
31	COL4A3 Gene Variants and Diabetic Kidney Disease in MODY. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1162-1171.	2.2	26
32	Social Determinants of Health Are Associated with Markers of Renal Injury in Adolescents with Type 1 Diabetes. <i>Journal of Pediatrics</i> , 2018, 198, 247-253.e1.	0.9	14
33	miR-370 promotes high glucose-induced podocyte injuries by inhibiting angiotensin II type 1 receptor-associated protein. <i>Cell Biology International</i> , 2018, 42, 1545-1555.	1.4	6
34	Association between hearing organ and renal function in young adult type 1 diabetic patients: A cross-sectional study. <i>Scientific Reports</i> , 2018, 8, 12645.	1.6	2
35	Kruppel-Like Transcription Factor-4 Gene Expression and DNA Methylation Status in Type 2 Diabetes and Diabetic Nephropathy Patients. <i>Archives of Medical Research</i> , 2019, 50, 91-97.	1.5	8
36	MiR-30e-5p and MiR-15a-5p Expressions in Plasma and Urine of Type 1 Diabetic Patients With Diabetic Kidney Disease. <i>Frontiers in Genetics</i> , 2019, 10, 563.	1.1	29
37	Dysregulation of histone H3 lysine 27 trimethylation in transforming growth factor- β 1-induced gene expression in mesangial cells and diabetic kidney. <i>Journal of Biological Chemistry</i> , 2019, 294, 12695-12707.	1.6	52

#	ARTICLE	IF	CITATIONS
38	Basic Research in Diabetic Nephropathy Health Care: A study of the Renoprotective Mechanism of Metformin. <i>Journal of Medical Systems</i> , 2019, 43, 266.	2.2	15
39	Diabetic kidney diseases revisited: A new perspective for a new era. <i>Molecular Metabolism</i> , 2019, 30, 250-263.	3.0	122
40	Impact of Kidney Function on Cardiovascular Risk and Mortality: A Comparison of South Asian and European Cohorts. <i>American Journal of Nephrology</i> , 2019, 50, 425-433.	1.4	14
41	Genetics of diabetic kidney disease: A follow-up study in the Arab population of the United Arab Emirates. <i>Molecular Genetics & Genomic Medicine</i> , 2019, 7, e985.	0.6	4
42	Inflammation Leads the Way on the ROADMAP to Diabetic Kidney Disease. <i>Kidney International Reports</i> , 2019, 4, 1362-1365.	0.4	5
43	Kidney cytosine methylation changes improve renal function decline estimation in patients with diabetic kidney disease. <i>Nature Communications</i> , 2019, 10, 2461.	5.8	59
44	Mitochondrial Activity and Skeletal Muscle Insulin Resistance in Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2751.	1.8	30
45	Genetic and Epigenetic Studies in Diabetic Kidney Disease. <i>Frontiers in Genetics</i> , 2019, 10, 507.	1.1	56
46	Cause-Specific Mortality in Multiethnic South East Asians With Type 2 Diabetes Mellitus. <i>Asia-Pacific Journal of Public Health</i> , 2019, 31, 306-314.	0.4	5
47	Whole transcriptome analysis of diabetic nephropathy in the db/db mouse model of type 2 diabetes. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 17520-17533.	1.2	19
48	Metabolic consequences of lactate dehydrogenase inhibition by oxamate in hyperglycemic proximal tubular cells. <i>Experimental Cell Research</i> , 2019, 378, 51-56.	1.2	13
49	Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review. <i>Journal of Medical Economics</i> , 2019, 22, 593-604.	1.0	47
50	Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>Endocrinology and Metabolism</i> , 2019, 34, 80.	1.3	42
51	Prompt apoptotic response to high glucose in SGLT-expressing renal cells. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, F1078-F1089.	1.3	15
52	Animal Models of Type 2 Diabetes, Obesity and Nonalcoholic Steatohepatitis – Clinical Translatability and Applicability in Preclinical Drug Development. , 2019, , 369-403.		4
53	Economic Burden and Health-Related Quality of Life Associated with Current Treatments for Anaemia in Patients with CKD not on Dialysis: A Systematic Review. <i>PharmacoEconomics - Open</i> , 2019, 3, 463-478.	0.9	18
54	Molecular Imaging of the Glomerulus via Mesangial Cell Uptake of Radiolabeled Tilmanocept. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1325-1332.	2.8	10
55	Association of diabetic retinopathy and diabetic macular oedema with renal function in southern Chinese patients with type 2 diabetes mellitus: a single-centre observational study. <i>BMJ Open</i> , 2019, 9, e031194.	0.8	45

#	ARTICLE	IF	CITATIONS
56	A complex auxiliary: IL-17/Th17 signaling during type 1 diabetes progression. <i>Molecular Immunology</i> , 2019, 105, 16-31.	1.0	14
57	Diabetic Kidney Disease. , 2019, , 42-61.e5.		1
58	Rapid decline of renal function in patients with type 2 diabetes with heavy proteinuria: a report of three cases. <i>BMC Nephrology</i> , 2019, 20, 22.	0.8	8
59	Vitamin D protects against diabetic nephropathy: Evidence-based effectiveness and mechanism. <i>European Journal of Pharmacology</i> , 2019, 845, 91-98.	1.7	40
60	Long non-coding RNA MALAT1 and microRNA-499a expression profiles in diabetic ESRD patients undergoing dialysis: a preliminary cross-sectional analysis. <i>Archives of Physiology and Biochemistry</i> , 2020, 126, 172-182.	1.0	24
61	Synergistic interaction of hypertension and diabetes on chronic kidney disease: Insights from the National Health and Nutrition Examination Survey 1999â€”2006. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107447.	1.2	6
62	Development of risk models for major adverse chronic renal outcomes among patients with type 2 diabetes mellitus using insurance claims: a retrospective observational study. <i>Current Medical Research and Opinion</i> , 2020, 36, 219-227.	0.9	7
63	-866G/A and Ins/Del polymorphisms in the UCP2 gene and diabetic kidney disease: case-control study and meta-analysis. <i>Genetics and Molecular Biology</i> , 2020, 43, e20180374.	0.6	1
64	Diabetic microcirculatory disturbances and pathologic erythropoiesis are provoked by deposition of amyloid-forming amylin in red blood cells and capillaries. <i>Kidney International</i> , 2020, 97, 143-155.	2.6	31
65	Primary Care Providersâ€™ Acceptance of Pharmacistsâ€™ Recommendations to Support Optimal Medication Management for Patients with Diabetic Kidney Disease. <i>Journal of General Internal Medicine</i> , 2020, 35, 63-69.	1.3	5
67	Diabetic Kidney Disease: Past and Present. <i>Advances in Anatomic Pathology</i> , 2020, 27, 87-97.	2.4	54
68	Comprehensive lipidomic profiling in serum and multiple tissues from a mouse model of diabetes. <i>Metabolomics</i> , 2020, 16, 115.	1.4	14
69	Renal protective effects of astragaloside IV, in diabetes mellitus kidney damage animal models: A systematic review, meta-analysis. <i>Pharmacological Research</i> , 2020, 160, 105192.	3.1	21
70	AGE/RAGE signaling-mediated endoplasmic reticulum stress and future prospects in non-coding RNA therapeutics for diabetic nephropathy. <i>Biomedicine and Pharmacotherapy</i> , 2020, 131, 110655.	2.5	38
71	Withaferin A protects against endoplasmic reticulum stress-associated apoptosis, inflammation, and fibrosis in the kidney of a mouse model of unilateral ureteral obstruction. <i>Phytomedicine</i> , 2020, 79, 153352.	2.3	19
72	The genetic map of diabetic nephropathy: evidence from a systematic review and meta-analysis of genetic association studies. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 768-781.	1.4	31
73	Mitochondrial pyruvate carrier: a potential target for diabetic nephropathy. <i>BMC Nephrology</i> , 2020, 21, 274.	0.8	6
74	Effects of ZnT8 on epithelial-to-mesenchymal transition and tubulointerstitial fibrosis in diabetic kidney disease. <i>Cell Death and Disease</i> , 2020, 11, 544.	2.7	9

#	ARTICLE	IF	CITATIONS
75	Diabetic Kidney Disease: Challenges, Advances, and Opportunities. <i>Kidney Diseases (Basel, Switzerland)</i> , 2020, 6, 215-225.	1.2	98
76	Empagliflozin improves diabetic renal tubular injury by alleviating mitochondrial fission via AMPK/SP1/PGAM5 pathway. <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154334.	1.5	50
77	Bariatric surgery for the treatment of chronic kidney disease in obesity and type 2 diabetes mellitus. <i>Nature Reviews Nephrology</i> , 2020, 16, 709-720.	4.1	64
78	Circ_0123996 promotes cell proliferation and fibrosis in mouse mesangial cells through sponging miR-149-5p and inducing Bach1 expression. <i>Gene</i> , 2020, 761, 144971.	1.0	28
79	Accelerated Kidney Aging in Diabetes Mellitus. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-24.	1.9	52
80	FOXO3a accumulation and activation accelerate oxidative stress-induced podocyte injury. <i>FASEB Journal</i> , 2020, 34, 13300-13316.	0.2	18
81	A Targeted Multiomics Approach to Identify Biomarkers Associated with Rapid eGFR Decline in Type 1 Diabetes. <i>American Journal of Nephrology</i> , 2020, 51, 839-848.	1.4	10
82	Gut microbiota profile and selected plasma metabolites in type 1 diabetes without and with stratification by albuminuria. <i>Diabetologia</i> , 2020, 63, 2713-2724.	2.9	27
83	Identification of hub genes in diabetic kidney disease via multiple-microarray analysis. <i>Annals of Translational Medicine</i> , 2020, 8, 997-997.	0.7	16
84	Early Detection of CKD: Implications for Low-Income, Middle-Income, and High-Income Countries. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1931-1940.	3.0	36
86	Sweet dreams: therapeutic insights, targeting imaging and physiologic evidence linking sleep, melatonin and diabetic nephropathy. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 522-530.	1.4	6
87	Mechanism of progression of diabetic kidney disease mediated by podocyte mitochondrial injury. <i>Molecular Biology Reports</i> , 2020, 47, 8023-8035.	1.0	19
88	Anti-inflammatory, antioxidant and renoprotective effects of SOCS1 mimetic peptide in the BTBR ob/ob mouse model of type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001242.	1.2	12
89	Metformin Protects against Podocyte Injury in Diabetic Kidney Disease. <i>Pharmaceuticals</i> , 2020, 13, 452.	1.7	11
90	Associations of serum uric acid level with diabetic retinopathy and albuminuria in patients with type 2 diabetes mellitus. <i>Journal of International Medical Research</i> , 2020, 48, 030006052096398.	0.4	13
91	Weighted gene co-expression network analysis identifies FCER1G as a key gene associated with diabetic kidney disease. <i>Annals of Translational Medicine</i> , 2020, 8, 1427-1427.	0.7	15
92	Multi-Omics Analysis of Diabetic Nephropathy Reveals Potential New Mechanisms and Drug Targets. <i>Frontiers in Genetics</i> , 2020, 11, 616435.	1.1	20
93	Discovery of polypodiside as a Keap1-dependent Nrf2 activator attenuating oxidative stress and accumulation of extracellular matrix in glomerular mesangial cells under high glucose. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115833.	1.4	8

#	ARTICLE	IF	CITATIONS
94	SNPs in PRKCA and HIF1A and GLUT1 are associated with diabetic kidney disease in a Chinese Han population with type 2 diabetes. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13264.	1.7	9
95	Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3798.	1.8	142
96	Development and validation of a predictive model for the progression of diabetic kidney disease to kidney failure. <i>Renal Failure</i> , 2020, 42, 550-559.	0.8	9
97	A common glomerular transcriptomic signature distinguishes diabetic kidney disease from other kidney diseases in humans and mice. <i>Current Research in Translational Medicine</i> , 2020, 68, 225-236.	1.2	2
98	The tubular hypothesis of nephron filtration and diabetic kidney disease. <i>Nature Reviews Nephrology</i> , 2020, 16, 317-336.	4.1	224
99	Lysosomal dysfunction-induced autophagic stress in diabetic kidney disease. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 8276-8290.	1.6	26
100	Renoprotective effects of Gushen Jiedu capsule on diabetic nephropathy in rats. <i>Scientific Reports</i> , 2020, 10, 2040.	1.6	10
101	<i>Panax notoginseng</i> preparations as adjuvant therapy for diabetic kidney disease: a systematic review and meta-analysis. <i>Pharmaceutical Biology</i> , 2020, 58, 138-145.	1.3	15
102	Cell junction proteins: Crossing the glomerular filtration barrier in diabetic nephropathy. <i>International Journal of Biological Macromolecules</i> , 2020, 148, 475-482.	3.6	48
103	Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 16-31.	2.2	91
105	Serum and urine metabolomics reveal potential biomarkers of T2DM patients with nephropathy. <i>Annals of Translational Medicine</i> , 2020, 8, 199-199.	0.7	24
106	20(S)-Ginsenoside Rg3 Protects Kidney from Diabetic Kidney Disease via Renal Inflammation Depression in Diabetic Rats. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-8.	1.0	11
107	Whole-Genome Sequencing of Finnish Type 1 Diabetic Siblings Discordant for Kidney Disease Reveals DNA Variants associated with Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 309-323.	3.0	10
108	Time-sequential correlations between diabetic kidney disease and diabetic retinopathy in type 2 diabetes: an 8-year prospective cohort study. <i>Acta Ophthalmologica</i> , 2021, 99, e1-e6.	0.6	14
109	Chemical constituents, clinical efficacy and molecular mechanisms of the ethanol extract of <i>Abelmoschus manihot</i> flowers in treatment of kidney diseases. <i>Phytotherapy Research</i> , 2021, 35, 198-206.	2.8	40
110	KCNQ1OT1/miR-18b/HMGGA2 axis regulates high glucose-induced proliferation, oxidative stress, and extracellular matrix accumulation in mesangial cells. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 321-331.	1.4	12
111	Shenyan Kangfu tablet alleviates diabetic kidney disease through attenuating inflammation and modulating the gut microbiota. <i>Journal of Natural Medicines</i> , 2021, 75, 84-98.	1.1	23
112	Potential Repressive Impact of microRNA-20a on Renal Tubular Damage in Diabetic Kidney Disease by Targeting C-X-C Motif Chemokine Ligand 6. <i>Archives of Medical Research</i> , 2021, 52, 58-68.	1.5	9

#	ARTICLE	IF	CITATIONS
113	Recent advances in drug discovery for diabetic kidney disease. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 447-461.	2.5	9
114	Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study. <i>Diabetes Care</i> , 2021, 44, 210-216.	4.3	14
115	Protective effect of carnosine on hydrogen peroxide-induced oxidative stress in human kidney tubular epithelial cells. <i>Biochemical and Biophysical Research Communications</i> , 2021, 534, 576-582.	1.0	14
116	Renal outcomes and all-cause death associated with sodium-glucose cotransporter 2 inhibitors versus other glucose-lowering drugs (<sc>CVD</sc> <sc>Korea</sc>). <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 455-466.	2.2	15
117	Epigenetic Histone Modifications in the Pathogenesis of Diabetic Kidney Disease. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 329-344.	1.1	10
118	The 100 top-cited articles in diabetic kidney disease: a bibliometric analysis. <i>Renal Failure</i> , 2021, 43, 781-795.	0.8	7
119	Rotten to the Cortex: Ceramide-Mediated Lipotoxicity in Diabetic Kidney Disease. <i>Frontiers in Endocrinology</i> , 2020, 11, 622692.	1.5	15
120	Negative correlation of urinary miR-199a-3p level with ameliorating effects of sarpogrelate and cilostazol in hypertensive diabetic nephropathy. <i>Biochemical Pharmacology</i> , 2021, 184, 114391.	2.0	6
121	Epigenetic modifications of Klotho expression in kidney diseases. <i>Journal of Molecular Medicine</i> , 2021, 99, 581-592.	1.7	17
122	Efficacy and safety of combination therapy with sodium-glucose cotransporter 2 inhibitors and renin-angiotensin system blockers in patients with type 2 diabetes: a systematic review and meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 720-729.	0.4	17
123	Therapeutic Potential of Mesenchymal Stem Cells in a Pre-Clinical Model of Diabetic Kidney Disease and Obesity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1546.	1.8	17
124	HMGB1 regulates ferroptosis through Nrf2 pathway in mesangial cells in response to high glucose. <i>Bioscience Reports</i> , 2021, 41, .	1.1	87
125	Fluorophore-Dapagliflozin Dyad for Detecting Diabetic Liver/Kidney Damages via Fluorescent Imaging and Treating Diabetes via Inhibiting SGLT2. <i>Analytical Chemistry</i> , 2021, 93, 4647-4656.	3.2	18
126	Targeted Delivery of Soluble Guanylate Cyclase (sGC) Activator Cinaciguat to Renal Mesangial Cells via Virus-Mimetic Nanoparticles Potentiates Anti-Fibrotic Effects by cGMP-Mediated Suppression of the TGF- β Pathway. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2557.	1.8	13
127	Improving the Dysregulation of FoxO1 Activity Is a Potential Therapy for Alleviating Diabetic Kidney Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 630617.	1.6	10
128	Effects of Curcumin on High Glucose-Induced Epithelial-to-Mesenchymal Transition in Renal Tubular Epithelial Cells Through the TLR4-NF- κ B Signaling Pathway. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 929-940.	1.1	4
129	Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. <i>Endocrinology and Metabolism</i> , 2021, 36, 388-400.	1.3	15
130	Fish oil replacement prevents, while docosahexaenoic acid-derived protectin DX mitigates end-stage renal disease in atherosclerotic diabetic mice. <i>FASEB Journal</i> , 2021, 35, e21559.	0.2	7

#	ARTICLE	IF	CITATIONS
131	A narrative review of new treatment options for chronic kidney disease in type 2 diabetes. <i>Annals of Translational Medicine</i> , 2021, 9, 716-716.	0.7	5
132	Association between renal function and retinal neurodegeneration in Chinese patients with type 2 diabetes mellitus. <i>Annals of Translational Medicine</i> , 2021, 9, 560-560.	0.7	5
133	Vitamin D/VDR Protects Against Diabetic Kidney Disease by Restoring Podocytes Autophagy. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 1681-1693.	1.1	18
134	RNA-Seq analysis reveals critical transcriptome changes caused by sodium butyrate in DN mouse models. <i>Bioscience Reports</i> , 2021, 41, .	1.1	7
135	Kidney Disease in Diabetic Patients: From Pathophysiology to Pharmacological Aspects with a Focus on Therapeutic Inertia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4824.	1.8	35
136	Lipid Accumulation Product is Associated with Urinary Albumin-creatinine Ratio in Chinese Prediabetic Population: A Report from the REACTION Study. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 2415-2425.	1.1	3
137	Finerenone: A Non-steroidal Mineralocorticoid Receptor Blocker for Diabetic Kidney Disease. <i>Trends in Endocrinology and Metabolism</i> , 2021, 32, 261-263.	3.1	3
138	Persons with type 1 diabetes have low blood oxygen levels in the supine and standing body positions. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001944.	1.2	6
139	Klotho protects against diabetic kidney disease via AMPK- and ERK-mediated autophagy. <i>Acta Diabetologica</i> , 2021, 58, 1413-1423.	1.2	22
140	Overexpression of lipoic acid synthase gene alleviates diabetic nephropathy <i>in</i> of <i>Lepr^{db/db}</i> mice. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002260.	1.2	6
141	Machine Learning for Predicting the 3-Year Risk of Incident Diabetes in Chinese Adults. <i>Frontiers in Public Health</i> , 2021, 9, 626331.	1.3	18
142	Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in <i>db/db</i> mice and KKAy mice compared with valsartan treatment. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, F1133-F1151.	1.3	20
143	The Multi-Therapeutic Role of MSCs in Diabetic Nephropathy. <i>Frontiers in Endocrinology</i> , 2021, 12, 671566.	1.5	18
144	Acute Kidney Injury in Pediatric Diabetic Kidney Disease. <i>Frontiers in Pediatrics</i> , 2021, 9, 668033.	0.9	10
145	Early Renoprotective Effect of Ruxolitinib in a Rat Model of Diabetic Nephropathy. <i>Pharmaceuticals</i> , 2021, 14, 608.	1.7	5
146	Prognostic evaluation model of diabetic nephropathy patients. <i>Annals of Palliative Medicine</i> , 2021, 10, 6867-6872.	0.5	8
147	Glomerular Endothelial Cells Are the Coordinator in the Development of Diabetic Nephropathy. <i>Frontiers in Medicine</i> , 2021, 8, 655639.	1.2	10
148	Editorial: Combating Diabetes and Diabetic Kidney Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 716029.	1.6	4

#	ARTICLE	IF	CITATIONS
149	Signaling Pathways Involved in Diabetic Renal Fibrosis. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 696542.	1.8	79
150	Icariin Ameliorates Diabetic Renal Tubulointerstitial Fibrosis by Restoring Autophagy via Regulation of the miR-192-5p/GLP-1R Pathway. <i>Frontiers in Pharmacology</i> , 2021, 12, 720387.	1.6	26
151	Ketone bodies for kidney injury and disease. <i>Advances in Redox Research</i> , 2021, 2, 100009.	0.9	16
152	Hyperpolarized pyruvate to measure the influence of PKM2 activation on glucose metabolism in the healthy kidney. <i>NMR in Biomedicine</i> , 2021, 34, e4583.	1.6	2
153	Extracellular vesicle-derived AEBP1 mRNA as a novel candidate biomarker for diabetic kidney disease. <i>Journal of Translational Medicine</i> , 2021, 19, 326.	1.8	14
155	Panax Ginseng C.A.Mey. as Medicine: The Potential Use of Panax Ginseng C.A.Mey. as a Remedy for Kidney Protection from a Pharmacological Perspective. <i>Frontiers in Pharmacology</i> , 2021, 12, 734151.	1.6	10
156	BGP-15 Inhibits Hyperglycemia-Aggravated VSMC Calcification Induced by High Phosphate. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9263.	1.8	4
157	The Loss of Mitochondrial Quality Control in Diabetic Kidney Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 706832.	1.8	20
158	Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus. <i>Europace</i> , 2021, 23, 1873-1891.	0.7	10
159	Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study. <i>Clinical Therapeutics</i> , 2021, 43, 1558-1573.	1.1	13
160	Flavonoids on diabetic nephropathy: advances and therapeutic opportunities. <i>Chinese Medicine</i> , 2021, 16, 74.	1.6	49
161	Single Cell Transcriptome Helps Better Understanding Crosstalk in Diabetic Kidney Disease. <i>Frontiers in Medicine</i> , 2021, 8, 657614.	1.2	5
162	Activated Histone Acetyltransferase p300/CBP-Related Signalling Pathways Mediate Up-Regulation of NADPH Oxidase, Inflammation, and Fibrosis in Diabetic Kidney. <i>Antioxidants</i> , 2021, 10, 1356.	2.2	17
163	Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 321, F149-F161.	1.3	16
164	Circular RNAs as Novel Diagnostic Biomarkers and Therapeutic Targets in Kidney Disease. <i>Frontiers in Medicine</i> , 2021, 8, 714958.	1.2	8
165	Autophagy Dysregulation in Diabetic Kidney Disease: From Pathophysiology to Pharmacological Interventions. <i>Cells</i> , 2021, 10, 2497.	1.8	18
166	Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 2749-2767.	5.7	121
167	Chronic Kidney Disease: Strategies to Retard Progression. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10084.	1.8	30

#	ARTICLE	IF	CITATIONS
168	Nomogram Prediction Model for Diabetic Retinopathy Development in Type 2 Diabetes Mellitus Patients: A Retrospective Cohort Study. <i>Journal of Diabetes Research</i> , 2021, 2021, 1-8.	1.0	11
169	Early type 1 diabetes aggravates renal ischemia/reperfusion-induced acute kidney injury. <i>Scientific Reports</i> , 2021, 11, 19028.	1.6	11
170	Epidemiological characteristics of diabetic kidney disease in Taiwan. <i>Journal of Diabetes Investigation</i> , 2021, 12, 2112-2123.	1.1	8
171	New progress in drugs treatment of diabetic kidney disease. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111918.	2.5	36
172	Diabetic proximal tubulopathy: Can we mimic the disease for in vitro screening of SGLT inhibitors?. <i>European Journal of Pharmacology</i> , 2021, 908, 174378.	1.7	3
174	Therapeutic potential of pro-resolving mediators in diabetic kidney disease. <i>Advanced Drug Delivery Reviews</i> , 2021, 178, 113965.	6.6	23
175	Relationship between the <i>FTO</i> Genotype and Early Chronic Kidney Disease in Type 2 Diabetes: The Mediating Role of Central Obesity, Hypertension, and High Albuminuria. <i>Lifestyle Genomics</i> , 2021, 14, 73-80.	0.6	4
176	Cardio- and reno-protective effects of dipeptidyl peptidase III in diabetic mice. <i>Journal of Biological Chemistry</i> , 2021, 296, 100761.	1.6	12
177	Comparison of urinary extracellular vesicle isolation methods for transcriptomic biomarker research in diabetic kidney disease. <i>Journal of Extracellular Vesicles</i> , 2020, 10, e12038.	5.5	39
178	Chronic Diabetes Complications: The Need to Move beyond Classical Concepts. <i>Trends in Endocrinology and Metabolism</i> , 2020, 31, 287-295.	3.1	94
179	A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology community. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 23-35.	1.4	10
180	Identification of Smad3-related transcriptomes in type 2 diabetic nephropathy by whole transcriptome RNA sequencing. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 2052-2068.	1.6	5
181	Functional methylome analysis of human diabetic kidney disease. <i>JCI Insight</i> , 2019, 4, .	2.3	54
182	Function of NADPH Oxidases in Diabetic Nephropathy and Development of Nox Inhibitors. <i>Biomolecules and Therapeutics</i> , 2020, 28, 25-33.	1.1	36
183	The Advances of Single-Cell RNA-Seq in Kidney Immunology. <i>Frontiers in Physiology</i> , 2021, 12, 752679.	1.3	4
185	The Pathogenesis of End-Stage Renal Disease from the Standpoint of the Theory of General Pathological Processes of Inflammation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11453.	1.8	22
186	Diagnostic Yield of Population-Based Screening for Chronic Kidney Disease in Low-Income, Middle-Income, and High-Income Countries. <i>JAMA Network Open</i> , 2021, 4, e2127396.	2.8	4
187	Urinary extracellular vesicles: Assessment of pre-analytical variables and development of a quality control with focus on transcriptomic biomarker research. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12158.	5.5	26

#	ARTICLE	IF	CITATIONS
188	Paraoxonase 1 (<i>PON1</i>) L55M and Q192R polymorphisms are not associated with chronic kidney disease in Thai individuals with type 2 diabetes. <i>International Journal of Clinical Practice</i> , 2021, 75, e14982.	0.8	0
189	Glomerular resistances predict long-term GFR decline in type 2 diabetic patients without overt nephropathy: a longitudinal subgroup analysis of the DEMAND trial. <i>Acta Diabetologica</i> , 2022, 59, 309-317.	1.2	2
190	Atypical Renal Clearance of Nanoparticles Larger Than the Kidney Filtration Threshold. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11182.	1.8	39
191	Mitochondria in Diabetic Kidney Disease. <i>Cells</i> , 2021, 10, 2945.	1.8	40
192	Bayesian Age-Period-Cohort Prediction of Mortality of Type 2 Diabetic Kidney Disease in China: A Modeling Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 767263.	1.5	7
193	Serum integrative omics reveals the landscape of human diabetic kidney disease. <i>Molecular Metabolism</i> , 2021, 54, 101367.	3.0	20
195	The role of circulating galectin-1 in type 2 diabetes and chronic kidney disease: evidence from cross-sectional, longitudinal and Mendelian randomisation analyses. <i>Diabetologia</i> , 2022, 65, 128-139.	2.9	7
196	Bioinformatics analysis of genes related to iron death in diabetic nephropathy through network and pathway levels based approaches. <i>PLoS ONE</i> , 2021, 16, e0259436.	1.1	24
197	RNA-binding proteins and their role in kidney disease. <i>Nature Reviews Nephrology</i> , 2022, 18, 153-170.	4.1	27
198	Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 46-57.	5.5	34
199	The Risk of Nephropathy, Retinopathy, and Leg Amputation in Patients With Diabetes and Hypertension: A Nationwide, Population-Based Retrospective Cohort Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 756189.	1.5	3
200	Effect of Curcumin on Diabetic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Clinical Trials. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-14.	0.5	4
201	Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1703-1713.	0.5	2
202	The clustering of Cardiovascular, Renal, Adipo-Metabolic Eye and Liver disease with type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2022, 128, 154961.	1.5	11
203	Adiponectin promotes repair of renal tubular epithelial cells by regulating mitochondrial biogenesis and function. <i>Metabolism: Clinical and Experimental</i> , 2022, 128, 154959.	1.5	18
204	Targeting the Pathobiology of Diabetic Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 282-289.	0.6	22
205	Diabetes mellitus contribution to the remodeling of the tumor microenvironment in gastric cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1997-2012.	0.8	4
206	Correlation between Inflammatory Factors and Bone Mineral Density in Postmenopausal Patients with Type 2 Diabetic Nephropathy. <i>Advances in Clinical Medicine</i> , 2022, 12, 549-553.	0.0	0

#	ARTICLE	IF	CITATIONS
207	Metabolic and hormonal responses to chronic blood-flow restricted resistance training in chronic kidney disease: a randomized trial. <i>Applied Physiology, Nutrition and Metabolism</i> , 2022, 47, 183-194.	0.9	8
208	Adenosine/A1R signaling pathway did not play dominant roles on the influence of SGLT2 inhibitor in the kidney of BSA-overloaded STZ-induced diabetic mice. <i>Journal of Diabetes Investigation</i> , 2022, , .	1.1	1
209	Activation of complement C1q and C3 in glomeruli might accelerate the progression of diabetic nephropathy: Evidence from transcriptomic data and renal histopathology. <i>Journal of Diabetes Investigation</i> , 2022, 13, 839-849.	1.1	13
210	Serum Amyloid A3 Promoter-Driven Luciferase Activity Enables Visualization of Diabetic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 899.	1.8	2
211	Predictive Ability of Visit-to-Visit Variability of HbA1c Measurements for the Development of Diabetic Kidney Disease: A Retrospective Longitudinal Observational Study. <i>Journal of Diabetes Research</i> , 2022, 2022, 1-11.	1.0	7
212	Improving annual albuminuria testing for individuals with diabetes. <i>BMJ Open Quality</i> , 2022, 11, e001591.	0.4	2
213	Healthy and unhealthy aging on kidney structure and function. <i>Current Opinion in Nephrology and Hypertension</i> , 2022, Publish Ahead of Print, .	1.0	5
214	Prediction of diabetic kidney disease with machine learning algorithms, upon the initial diagnosis of type 2 diabetes mellitus. <i>BMJ Open Diabetes Research and Care</i> , 2022, 10, e002560.	1.2	32
215	NAD(P)H: quinone oxidoreductase 1 attenuates oxidative stress and apoptosis by regulating Sirt1 in diabetic nephropathy. <i>Journal of Translational Medicine</i> , 2022, 20, 44.	1.8	33
216	A clinical and in-silico study of MicroRNA-21 and growth differentiation factor-15 expression in pre-diabetes, type 2 diabetes and diabetic nephropathy. <i>Minerva Endocrinology</i> , 2022, , .	0.6	4
217	JMJD1A/NR4A1 Signaling Regulates the Procession of Renal Tubular Epithelial Interstitial Fibrosis Induced by AGEs in HK-2. <i>Frontiers in Medicine</i> , 2021, 8, 807694.	1.2	5
218	AWAREness of Diagnosis and Treatment of Chronic Kidney Disease in Adults With Type 2 Diabetes (AWARE-CKD in T2D). <i>Canadian Journal of Diabetes</i> , 2022, 46, 464-472.	0.4	6
219	Diabetes in general. , 2022, , 27-92.		1
220	KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD. <i>American Journal of Kidney Diseases</i> , 2022, 79, 457-479.	2.1	18
221	Pharmacotherapy to delay the progression of diabetic kidney disease in people with type 2 diabetes: past, present and future. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2022, 13, 204201882210816.	1.4	10
222	MicroRNA-122-5p ameliorates tubular injury in diabetic nephropathy via FIH-1/HIF-1 pathway. <i>Renal Failure</i> , 2022, 44, 293-303.	0.8	11
224	Low-grade proteinuria and atherosclerotic cardiovascular disease: A transition study of patients with diabetic kidney disease. <i>PLoS ONE</i> , 2022, 17, e0264568.	1.1	1
225	Asparaginyl endopeptidase protects against podocyte injury in diabetic nephropathy through cleaving cofilin-1. <i>Cell Death and Disease</i> , 2022, 13, 184.	2.7	7

#	ARTICLE	IF	CITATIONS
226	Pathophysiologic Mechanisms and Potential Biomarkers in Diabetic Kidney Disease. <i>Diabetes and Metabolism Journal</i> , 2022, 46, 181-197.	1.8	48
227	Fungus-Derived 3-Hydroxyterphenyllin and Candidusin A Ameliorate Palmitic Acid-Induced Human Podocyte Injury via Anti-Oxidative and Anti-Apoptotic Mechanisms. <i>Molecules</i> , 2022, 27, 2109.	1.7	3
228	Implementation of Cardiometabolic Centers and Training Programs. <i>Current Diabetes Reports</i> , 2022, , 1.	1.7	0
229	Glycemic control and atrial fibrillation: an intricate relationship, yet under investigation. <i>Cardiovascular Diabetology</i> , 2022, 21, 39.	2.7	19
230	Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1197-1205.	2.2	9
231	Renal and Inflammatory Proteins as Biomarkers of Diabetic Kidney Disease and Lupus Nephritis. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-11.	1.9	10
232	Fecal Microbiota Transplant in a Pre-Clinical Model of Type 2 Diabetes Mellitus, Obesity and Diabetic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3842.	1.8	23
233	Studying Kidney Diseases Using Organoid Models. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 845401.	1.8	9
234	Glomerular hyperfiltration. <i>Nature Reviews Nephrology</i> , 2022, 18, 435-451.	4.1	60
235	Obesity-related glomerulopathy: Current approaches and future perspectives. <i>Obesity Reviews</i> , 2022, 23, e13450.	3.1	26
236	Mitochondrial dysfunction in diabetic tubulopathy. <i>Metabolism: Clinical and Experimental</i> , 2022, 131, 155195.	1.5	40
237	Advancements in nanomedicines for the detection and treatment of diabetic kidney disease. <i>Biomaterials and Biosystems</i> , 2022, 6, 100047.	1.0	2
238	Indoxyl Sulfate Elevated Lnc-SLC15A1-1 Upregulating CXCL10/CXCL8 Expression in High-Glucose Endothelial Cells by Sponging MicroRNAs. <i>Toxins</i> , 2021, 13, 873.	1.5	4
239	SGLT1-specific inhibition ameliorates renal failure and alters the gut microbial community in mice with adenine-induced renal failure. <i>Physiological Reports</i> , 2021, 9, e15092.	0.7	15
240	Roles of SIRT6 in kidney disease: a novel therapeutic target. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 1.	2.4	17
241	The cGAS-STING pathway: more than fighting against viruses and cancer. <i>Cell and Bioscience</i> , 2021, 11, 209.	2.1	22
242	Diabetic kidney disease-predisposing proinflammatory and profibrotic genes identified by weighted gene co-expression network analysis (WGCNA). <i>Journal of Cellular Biochemistry</i> , 2022, 123, 481-492.	1.2	18
243	Simultaneous in-vivo characterization of blood oxygen saturation and perfusion with bimodal multispectral optoacoustic tomography and ultrafast ultrasound Doppler imaging.. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
244	Prediction of 3-year risk of diabetic kidney disease using machine learning based on electronic medical records. <i>Journal of Translational Medicine</i> , 2022, 20, 143.	1.8	28
245	Identification of histopathological and clinical spectrum of diabetic kidney disease based on an unsupervised hierarchical clustering analysis of elderly autopsy specimens. <i>Nephrology</i> , 2022, , .	0.7	0
246	Cardiovascular Characteristics of Zucker Fatty Diabetes Mellitus Rats, an Animal Model for Obesity and Type 2 Diabetes. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4228.	1.8	1
247	Soluble tumor necrosis factor receptor 2 is associated with progressive diabetic kidney disease in patients with type 2 diabetes mellitus. <i>PLoS ONE</i> , 2022, 17, e0266854.	1.1	5
248	Long Non-Coding RNAs in the Pathogenesis of Diabetic Kidney Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 845371.	1.8	6
249	Implications of fibrotic extracellular matrix in diabetic retinopathy. <i>Experimental Biology and Medicine</i> , 2022, 247, 1093-1102.	1.1	2
256	The physiological and pathophysiological roles of carbohydrate response element binding protein in the kidney. <i>Endocrine Journal</i> , 2022, , .	0.7	0
257	Cholesterol Metabolism in Chronic Kidney Disease: Physiology, Pathologic Mechanisms, and Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1372, 119-143.	0.8	5
258	Diabetic Retinopathy Is a Predictor of Progression of Diabetic Kidney Disease: A Systematic Review and Meta-Analysis. <i>International Journal of Nephrology</i> , 2022, 2022, 1-11.	0.7	8
259	A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2022, 395, 867-885.	1.4	12
260	Recent advances in the pharmacotherapeutic management of diabetic kidney disease. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 791-803.	0.9	5
261	Modified lipid metabolism and cytosolic phospholipase A2 activation in mesangial cells under pro-inflammatory conditions. <i>Scientific Reports</i> , 2022, 12, 7322.	1.6	3
262	Influence of Tangeretin on the Exponential Regression of Inflammation and Oxidative Stress in Streptozotocin-Induced Diabetic Nephropathy. <i>Applied Biochemistry and Biotechnology</i> , 2022, 194, 3914-3929.	1.4	6
263	Isoliquiritigenin ameliorates advanced glycation end-products toxicity on renal proximal tubular epithelial cells. <i>Environmental Toxicology</i> , 2022, 37, 2096-2102.	2.1	7
264	Biochemical mechanism underlying the pathogenesis of diabetic retinopathy and other diabetic complications in humans: the methanol-formaldehyde-formic acid hypothesis. <i>Acta Biochimica Et Biophysica Sinica</i> , 2022, 54, 415-451.	0.9	0
265	Bruceine A protects against diabetic kidney disease via inhibiting galectin-1. <i>Kidney International</i> , 2022, 102, 521-535.	2.6	7
266	Precision Nephrology in Patients with Diabetes and Chronic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5719.	1.8	3
267	Comparison of Nonalbuminuric and Albuminuric Diabetic Kidney Disease Among Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>Frontiers in Endocrinology</i> , 2022, 13, .	1.5	14

#	ARTICLE	IF	CITATIONS
269	Renal biopsy in patients with diabetes: Yesterday, today, and tomorrow. <i>Diabetic Nephropathy</i> , 2021, 1, 59-62.	0.1	0
270	Renoprotective mechanisms of SGLT2 inhibitor in diabetic kidney disease. <i>Diabetic Nephropathy</i> , 2022, .	0.1	0
271	Protective effect of the tunneling nanotube-TNFAIP2/M-sec system on podocyte autophagy in diabetic nephropathy. <i>Autophagy</i> , 2023, 19, 505-524.	4.3	28
272	Identifying Distinct Risk Thresholds of Glycated Hemoglobin and Systolic Blood Pressure for Rapid Albuminuria Progression in Type 2 Diabetes From NHANES (1999â€“2018). <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
273	LncRNA MALAT1 Aggravates Renal Tubular Injury via Activating LIN28A and the Nox4/AMPK/mTOR Signaling Axis in Diabetic Nephropathy. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	4
274	Effects of Qidantang Granule on early stage of diabetic kidney disease in rats. <i>Aging</i> , 2022, 14, 4888-4896.	1.4	4
275	Efficacy and Safety of Non-Steroidal Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review Incorporating an Indirect Comparisons Meta-Analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
276	Plasma and urinary extracellular vesicle microRNAs and their related pathways in diabetic kidney disease. <i>Genomics</i> , 2022, 114, 110407.	1.3	7
277	Diosgenin protects against podocyte injury in early phase of diabetic nephropathy through regulating SIRT6. <i>Phytomedicine</i> , 2022, 104, 154276.	2.3	12
278	Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1448-1457.	2.2	13
279	Cellular Senescence and Regulated Cell Death of Tubular Epithelial Cells in Diabetic Kidney Disease. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	31
280	The Complement System in Metabolic-Associated Kidney Diseases. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
281	Risk trajectories of complications in over one thousand newly diagnosed individuals with type 2 diabetes. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
282	TFP5-Mediated CDK5 Activity Inhibition Improves Diabetic Nephropathy via NGF/Sirt1 Regulating Axis. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	2
283	Prediction of cellular targets in diabetic kidney diseases with single-cell transcriptomic analysis of db/db mouse kidneys. <i>Journal of Cell Communication and Signaling</i> , 2023, 17, 169-188.	1.8	6
284	Identification of key genes and biological regulatory mechanisms in diabetic nephropathy: Meta-analysis of gene expression datasets. <i>Nefrologia</i> , 2023, 43, 575-586.	0.2	1
285	Nephroprotective Effects of Semaglutide as Mono- and Combination Treatment with Lisinopril in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease. <i>Biomedicines</i> , 2022, 10, 1661.	1.4	5
287	Evaluation of N-(6-[18F]Fluoropyridin-3-yl)glycine PET renography to detect renal function progression in a rat model of diabetic nephropathy. <i>Nuclear Medicine and Biology</i> , 2022, 112-113, 59-65.	0.3	0

#	ARTICLE	IF	CITATIONS
288	A Glimpse of Inflammation and Anti-Inflammation Therapy in Diabetic Kidney Disease. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	7
289	The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2022, 13, 204201882211124.	1.4	9
290	5-Hydroxymethylcytosine profiles in plasma cell-free DNA reflect molecular characteristics of diabetic kidney disease. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	2
291	Association Between Serum Albumin Level and Microvascular Complications of Type 2 Diabetes Mellitus. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 15, 2173-2182.	1.1	7
292	ZnT8 Exerts Anti-apoptosis of Kidney Tubular Epithelial Cell in Diabetic Kidney Disease Through TNFAIP3-NF- κ B Signal Pathways. <i>Biological Trace Element Research</i> , 2023, 201, 2442-2457.	1.9	3
293	Antioxidant and Anti-Inflammatory Properties of Hydroxyl Safflower Yellow a in Diabetic Nephropathy: A Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
294	Evaluation of the clinical utility of the PromarkerD in-vitro test in predicting diabetic kidney disease and rapid renal decline through a conjoint analysis. <i>PLoS ONE</i> , 2022, 17, e0271740.	1.1	1
295	The Epidemiology of Diabetic Kidney Disease. <i>Kidney and Dialysis</i> , 2022, 2, 433-442.	0.5	29
296	Diabetes and Cardiorenal Complications: A Clinical Review of Existing Therapies and Novel Combinations, Focusing on SGLT2 Inhibitors. <i>Current Diabetes Reviews</i> , 2022, 19, .	0.6	1
297	The role of vitamin D receptor agonist on podocyte injury induced by high glucose. <i>Diabetic Nephropathy</i> , 2022, .	0.1	0
298	How does diabetes cause susceptibility to COVID-19 in the kidney: new clues provided by organoids. <i>Kidney International</i> , 2022, 102, 951-953.	2.6	1
299	MD Simulation Studies for Selective Phytochemicals as Potential Inhibitors against Major Biological Targets of Diabetic Nephropathy. <i>Molecules</i> , 2022, 27, 4980.	1.7	5
300	The roles of hydrogen sulfide in renal physiology and disease states. <i>Renal Failure</i> , 2022, 44, 1290-1309.	0.8	8
301	Interaction between Plasma Metabolomics and Intestinal Microbiome in db/db Mouse, an Animal Model for Study of Type 2 Diabetes and Diabetic Kidney Disease. <i>Metabolites</i> , 2022, 12, 775.	1.3	15
302	Serum Metabolites and Kidney Outcomes: The Atherosclerosis Risk in Communities Study. <i>Kidney Medicine</i> , 2022, 4, 100522.	1.0	6
303	A Review on the Pharmacological Activities of <i>Salvia Miltiorrhizae Radix</i> Using International Classification of Disease, 10th Revision (ICD-10) Codes. <i>Processes</i> , 2022, 10, 1860.	1.3	0
304	Artificial Intelligence in Efficient Diabetes Care. <i>Current Diabetes Reviews</i> , 2023, 19, .	0.6	2
305	Risk Factors of Pancreatic Cancer in Patients With Type 2 Diabetes Mellitus: The Hong Kong Diabetes Study. <i>Journal of the Endocrine Society</i> , 2022, 6, .	0.1	2

#	ARTICLE	IF	CITATIONS
306	Spatially resolved whole transcriptome profiling in human and mouse tissue using Digital Spatial Profiling. <i>Genome Research</i> , 0, , .	2.4	9
307	A Selective Adenosine A ₃ Receptor Antagonist, HL3501, Has Therapeutic Potential in Preclinical Liver and Renal Fibrosis Models. <i>In Vivo</i> , 2022, 36, 2186-2193.	0.6	4
308	MicroRNA control of kidney disease. , 2022, , 401-428.		0
309	Effect of Influenza Vaccination on the Reduction of the Incidence of Chronic Kidney Disease and Dialysis in Patients with Type 2 Diabetes Mellitus. <i>Journal of Clinical Medicine</i> , 2022, 11, 4520.	1.0	2
310	Clinical efficacy, safety, and cost of nine Chinese patent medicines combined with ACEI/ARB in the treatment of early diabetic kidney disease: A network meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
311	Therapeutic potential of conditioned medium obtained from deferoxamine preconditioned umbilical cord mesenchymal stem cells on diabetic nephropathy model. <i>Stem Cell Research and Therapy</i> , 2022, 13, .	2.4	10
312	Association of amino acids related to urea cycle with risk of diabetic nephropathy in two independent cross-sectional studies of Chinese adults. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1
313	O-GlcNAcylation in Renal (Patho)Physiology. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11260.	1.8	6
314	Urinary Angiotensinogen in Patients With Type 1 Diabetes With Microalbuminuria: Gender Differences and Effect of Intensive Insulin Therapy. <i>Kidney International Reports</i> , 2022, 7, 2657-2667.	0.4	1
315	Ferroptosis is involved in corpus cavernosum smooth muscle cells impairment in diabetes mellitus-induced erectile dysfunction. <i>Andrology</i> , 2023, 11, 332-343.	1.9	8
316	Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10882.	1.8	9
317	Insulin Resistance and Type 2 Diabetes Mellitus: An Ultimatum to Renal Physiology. <i>Cureus</i> , 2022, , .	0.2	1
318	Plasma galectin-3 concentration and estimated glomerular filtration rate in patients with type 2 diabetes with and without albuminuria. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
319	Immune repertoire and evolutionary trajectory analysis in the development of diabetic nephropathy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
320	Is Bariatric Surgery improving mitochondrial function in the renal cells of patients with obesity-induced kidney disease?. <i>Pharmacological Research</i> , 2022, , 106488.	3.1	0
321	Proteinuria in early referral to spectral domain optical coherence tomography for macular edema detection in type 2 diabetes individuals: results from the Brazilian Diabetes Study. <i>Current Medical Research and Opinion</i> , 0, , 1-21.	0.9	0
322	Podocyte developmental pathways in diabetic nephropathy: A spotlight on Notch signaling. <i>Diabetic Nephropathy</i> , 2022, 2, 1-6.	0.1	2
323	Urinary RBP as an Independent Predictor of Renal Outcome in Diabetic Nephropathy. <i>Disease Markers</i> , 2022, 2022, 1-13.	0.6	2

#	ARTICLE	IF	CITATIONS
324	Comorbidity phenotypes and risk of mortality in patients with osteoarthritis in the UK: a latent class analysis. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	5
326	The role of lncRNAs in regulation of DKD and diabetes-related cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
328	Resistant Starch as a Dietary Intervention to Limit the Progression of Diabetic Kidney Disease. <i>Nutrients</i> , 2022, 14, 4547.	1.7	7
329	Acetyl Co-A Carboxylase Inhibition Halts Hyperglycemia Induced Upregulation of De Novo Lipogenesis in Podocytes and Proximal Tubular Cells. <i>Metabolites</i> , 2022, 12, 940.	1.3	1
330	Genome-wide DNA methylation analysis of extreme phenotypes in the identification of novel epigenetic modifications in diabetic retinopathy. <i>Clinical Epigenetics</i> , 2022, 14, .	1.8	4
331	Zuogui Wan ameliorates high glucose-induced podocyte apoptosis and improves diabetic nephropathy in db/db mice. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
332	Therapeutic mechanism and clinical application of Chinese herbal medicine against diabetic kidney disease. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
333	Rewriting Medical Textbooks: The Kidney as a Window to the Heart – The Role of Sodium–Glucose Transport Protein 2 Inhibitors in Cardiovascular and Renal Disease in Type 2 Diabetes Mellitus. <i>European Medical Journal Diabetes</i> , 0, , 36-45.	4.0	0
334	A comprehensive weighted gene co-expression network analysis uncovers potential targets in diabetic kidney disease. <i>Journal of Translational Internal Medicine</i> , 2022, .	1.0	0
335	Subclinical Acute Kidney Injury in COVID-19: Possible Mechanisms and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14193.	1.8	6
336	Mesenchymal stromal cell therapy compared to SGLT2-inhibitors and usual care in treating diabetic kidney disease: A cost-effectiveness analysis. <i>PLoS ONE</i> , 2022, 17, e0274136.	1.1	1
337	Sodium–glucose co-transporter 2 inhibitors for the treatment of cardio-renal syndrome. <i>European Heart Journal Supplements</i> , 2022, 24, I68-I71.	0.0	3
338	Synergistic effect of chronic kidney disease, neuropathy, and retinopathy on all-cause mortality in type 1 and type 2 diabetes: a 21-year longitudinal study. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	9
339	Antioxidant and anti-inflammatory activities of <i>Centratherum anthelminticum</i> (L.) Kuntze seed oil in diabetic nephropathy via modulation of Nrf-2/HO-1 and NF- κ B pathway. <i>BMC Complementary Medicine and Therapies</i> , 2022, 22, .	1.2	1
340	Additive interaction of diabetes mellitus and chronic kidney disease in cancer patient mortality risk. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
341	Study on the relationship between lipoprotein (a) and diabetic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2023, 37, 108378.	1.2	2
342	Podocyte derived <sc>TNF</sc> α mediates monocyte differentiation and contributes to glomerular injury. <i>FASEB Journal</i> , 2022, 36, .	0.2	7
344	ASH2L Aggravates Fibrosis and Inflammation through HIPK2 in High Glucose-Induced Glomerular Mesangial Cells. <i>Genes</i> , 2022, 13, 2244.	1.0	5

#	ARTICLE	IF	CITATIONS
345	Whole-exome sequencing study identifies four novel gene loci associated with diabetic kidney disease. <i>Human Molecular Genetics</i> , 2023, 32, 1048-1060.	1.4	3
346	Chronic kidney disease in patients with type 2 diabetes: new targets of medicine action. <i>Diabetes Mellitus</i> , 2022, 25, 492-498.	0.5	3
347	Identifying myoglobin as a mediator of diabetic kidney disease: a machine learning-based cross-sectional study. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
348	Validation of a risk prediction model for early chronic kidney disease in patients with type 2 diabetes: Data from the German/Austrian Diabetes Prospective Follow-up registry. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 776-784.	2.2	1
349	Elajik Asit, Diyabetik B�rbrek Hasarında TGF�21/Smad Kaynaklı B�rbrek Fibrozisini �nhibe Eder. <i>Duzce Universitesi Tıp Fak�ltesi Dergisi</i> , 2022, 24, 321-327.	0.3	2
350	Structural and Functional Changes in Aging Kidneys. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15435.	1.8	12
352	Use of Estimated Glomerular Filtration Rate and Urine Albumin-to-Creatinine Ratio Based on KDIGO 2012 Guideline in a Thai Community Hospital: Prevalence of Chronic Kidney Disease and its Risk Factors. <i>Medical Science Monitor Basic Research</i> , 0, 28, .	2.6	0
353	Risk factors of chronic kidney disease among type 2 diabetic patients with longer duration of diabetes. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	6
354	Strong negative association of non-HDL cholesterol goal achievement with incident CKD among adults with diabetes. <i>Journal of the Endocrine Society</i> , 0, , .	0.1	0
355	Whether Renal Pathology Is an Independent Predictor for End-Stage Renal Disease in Diabetic Kidney Disease Patients with Nephrotic Range Proteinuria: A Biopsy-Based Study. <i>Journal of Clinical Medicine</i> , 2023, 12, 88.	1.0	1
356	Beraprost Sodium Delays the Decline of Glomerular Filtration Rate in Patients with Diabetic Nephropathy: A Retrospective Study. <i>Diabetes Therapy</i> , 0, , .	1.2	0
357	Single-cell transcriptomics reveals a mechanosensitive injury signaling pathway in early diabetic nephropathy. <i>Genome Medicine</i> , 2023, 15, .	3.6	8
358	Cellular mechanism of action of forsythiaside for the treatment of diabetic kidney disease. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
359	Network Pharmacology Approach to Investigate the Mechanism of Danggui-Shaoyao-San against Diabetic Kidney Disease. <i>Evidence-based Complementary and Alternative Medicine</i> , 2023, 2023, 1-12.	0.5	0
361	Succinate-SUCNR1 induces renal tubular cell apoptosis. <i>American Journal of Physiology - Cell Physiology</i> , 2023, 324, C467-C476.	2.1	4
362	Urinary Biomarkers of Tubular Health and Risk for Kidney Function Decline or Mortality in Diabetes. <i>American Journal of Nephrology</i> , 2022, 53, 775-785.	1.4	4
363	Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity. <i>Peptides</i> , 2023, 162, 170955.	1.2	5
364	Reduced methylation correlates with diabetic nephropathy risk in type 1 diabetes. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	8

#	ARTICLE	IF	CITATIONS
365	Single-cell transcriptomics: A new tool for studying diabetic kidney disease. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	5
366	Chinese expert consensus on the risk assessment and management of panvascular disease inpatients with type 2 diabetes mellitus (2022 edition). <i>Cardiology Plus</i> , 2022, 7, 162-177.	0.2	5
367	A comprehensive weighted gene co-expression network analysis uncovers potential targets in diabetic kidney disease. <i>Journal of Translational Internal Medicine</i> , 2023, 10, 359-368.	1.0	3
368	<i>Abelmoschus Manihot</i> ameliorates the levels of circulating metabolites in diabetic nephropathy by modulating gut microbiota in non-obese diabetes mice. <i>Microbial Biotechnology</i> , 2023, 16, 813-826.	2.0	6
369	Hyperactivation of YAP/TAZ Drives Alterations in Mesangial Cells through Stabilization of N-Myc in Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2023, 34, 809-828.	3.0	6
370	Anemia is a risk factor for rapid eGFR decline in type 2 diabetes. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	4
371	Identification of key genes and biological regulatory mechanisms in diabetic nephropathy: Meta-analysis of gene expression datasets. <i>Nefrologia</i> , 2023, 43, 575-586.	0.2	1
372	Gut microbiota and its metabolites – molecular mechanisms and management strategies in diabetic kidney disease. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
373	Development of a metabolite-based deep learning algorithm for clinical precise diagnosis of the progression of diabetic kidney disease. <i>Biomedical Signal Processing and Control</i> , 2023, 83, 104625.	3.5	3
374	Obesity and renal disease: Benefits of bariatric surgery. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	1
375	Glucagon-like peptide-1 receptor agonists to expand the healthy lifespan: Current and future potentials. <i>Aging Cell</i> , 2023, 22, .	3.0	1
376	Diabetes Mellitus and the Kidneys. <i>Veterinary Clinics of North America - Small Animal Practice</i> , 2023, 53, 565-580.	0.5	1
377	Intestinal microbiome diversity of diabetic and non-diabetic kidney disease: Current status and future perspective. <i>Life Sciences</i> , 2023, 316, 121414.	2.0	3
378	The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes. <i>Cell Metabolism</i> , 2023, 35, 253-273.	7.2	16
379	miR-124 improves mitochondrial function of renal tubular epithelial cells in <i>db/db</i> mice. <i>FASEB Journal</i> , 2023, 37, .	0.2	4
380	Molecular pathways that drive diabetic kidney disease. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	61
381	A Review of Medicinal Plants with Renoprotective Activity in Diabetic Nephropathy Animal Models. <i>Life</i> , 2023, 13, 560.	1.1	9
382	The association of plasma NT-proBNP level and progression of diabetic kidney disease. <i>Renal Failure</i> , 2023, 45, .	0.8	1

#	ARTICLE	IF	CITATIONS
383	Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: A systematic review and network meta-analysis of randomized controlled trials. <i>Diabetes Research and Clinical Practice</i> , 2023, 198, 110592.	1.1	5
384	Evidence of SARS-CoV-2 infection in postmortem lung, kidney, and liver samples, revealing cellular targets involved in COVID-19 pathogenesis. <i>Archives of Virology</i> , 2023, 168, .	0.9	3
385	Analysis of urine Raman spectra differences from patients with diabetes mellitus and renal pathologies. <i>PeerJ</i> , 0, 11, e14879.	0.9	4
386	The effect of metabolic dysfunction-associated fatty liver disease and diabetic kidney disease on the risk of hospitalization of heart failure in type 2 diabetes: a retrospective cohort study. <i>Diabetology and Metabolic Syndrome</i> , 2023, 15, .	1.2	1
387	Associations of serum amino acids related to urea cycle with risk of chronic kidney disease in Chinese with type 2 diabetes. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	0
388	Ginsenoside Rg3 has effects comparable to those of ginsenoside re on diabetic kidney disease prevention in db/db mice by regulating inflammation, fibrosis and PPAR β . <i>Molecular Medicine Reports</i> , 2023, 27, .	1.1	0
389	Acacetin attenuates the pancreatic and hepatorenal dysfunction in type 2 diabetic rats induced by high-fat diet combined with streptozotocin. <i>Journal of Natural Medicines</i> , 2023, 77, 446-454.	1.1	1
390	Zinc Alpha 2 Glycoprotein as an Early Biomarker of Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients. <i>Cureus</i> , 2023, , .	0.2	0
391	Endothelial Autophagy Dysregulation in Diabetes. <i>Cells</i> , 2023, 12, 947.	1.8	4
393	Single-cell RNA and transcriptome sequencing profiles identify immune-associated key genes in the development of diabetic kidney disease. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
394	Echinochrome A Prevents Diabetic Nephropathy by Inhibiting the PKC- ι Pathway and Enhancing Renal Mitochondrial Function in db/db Mice. <i>Marine Drugs</i> , 2023, 21, 222.	2.2	1
395	Ginsenoside Rg1 treatment alleviates renal fibrosis by inhibiting the NOX4 \rightarrow MAPK pathway in T2DM mice. <i>Renal Failure</i> , 2023, 45, .	0.8	4
396	Diabetic vascular diseases: molecular mechanisms and therapeutic strategies. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	42
398	An update on the role of thioredoxin-interacting protein in diabetic kidney disease: A mini review. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	2
399	Genome-wide mRNA profiling in urinary extracellular vesicles reveals stress gene signature for diabetic kidney disease. <i>IScience</i> , 2023, 26, 106686.	1.9	4
410	Renal Disease in Diabetes. , 2023, , 905-922.		0
416	Lipoproteins and Diabetic Kidney Disease. <i>Contemporary Diabetes</i> , 2023, , 407-438.	0.0	0
423	Review article: Type 2 diabetes mellitus: Pathogenesis and therapeutic intervention. <i>AIP Conference Proceedings</i> , 2023, , .	0.3	0

#	ARTICLE	IF	CITATIONS
428	Genetics of Diabetic Kidney Disease in Type 2 Diabetes: Candidate Gene Studies and Genome-Wide Association Studies (GWAS). Journal of the Indian Institute of Science, 0, , .	0.9	0
440	Effect of Electromagnetic Radiation on Simulated Sweat Gland Under Diabetes and Diabetic Kidney Disease. Algorithms for Intelligent Systems, 2023, , 463-473.	0.5	0
452	Editorial: Receptor biology and cell signaling in diabetes: volume II. Frontiers in Pharmacology, 0, 14, .	1.6	0
457	Inter-organ crosstalk during development and progression of type 2 diabetes mellitus. Nature Reviews Endocrinology, 2024, 20, 27-49.	4.3	7
463	Epidemiology and Pathogenesis of Type 1 Diabetes. , 2023, , 13-39.		0